non-small-cell lung cancer
Conditions
Interventions
sequential radiation therapy followed by immune checkpoint inhibitor(ICI)+ cytotoxic chemotherapy continuation
Sponsors
National Hospital Organization Shikoku Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -The patient has histologically or cytologically confirmed non-small cell lung cancer. -The patient has clinical stage III, IV, or post-operative recurrent non-small cell lung cancer that is not amenable to radical resection or radical radiation therapy. -The patient has Oligo-PD after treatment with an immune checkpoint inhibitor (ICI) plus platinum-based cytotoxic anticancer agent. <The Oligo-PD is defined as meeting all four of the following.> 1.Two or more courses of ICI+chemo induction and two or more courses of maintenance therapy, and tumor reduction of SD or greater with reduction. 2.The lesions that do not result in PD on RECIST as a whole if they are not exacerbated after ICI+chemo maintenance therapy and there is no exacerbation of the lesions. 3.The lesion must have no more than 3 lesions, including brain metastases, that are not in contact or fused by CT or MRI, respectively. However, lymph node metastases will be treated as a single lesion if the radiotherapist determines that the area can be irradiated at once. 4.Cases of cancerous pleural effusion, cancerous pericarditis, exacerbation in lymphangitis or cases of cancerous meningitis complications are excluded. -All of these Oligo-PDs are capable of additional radiation exposure. -An ECOG performance status (PS) of 0 to 1. -Major organ function is intact. -The patient is judged to be alive for at least 3 months from the date of enrollment.
Exclusion criteria
Exclusion criteria: Patients with serious complications or history are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, progression-free survival, safety, post-treatment status | — |
Countries
Japan
Contacts
Public ContactTakashi Ninomiya
National Hospital Organization Shikoku Cancer Center Clinical Research Promotion Department
Outcome results
None listed